# A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

> **NCT02588261** · PHASE3 · TERMINATED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 530 (actual)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** naquotinib mesilate
- **DRUG:** Erlotinib
- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT02588261
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-11
- **Primary completion:** 2017-12-21
- **Final completion:** 2017-12-21
- **Target enrollment:** 530 (ACTUAL)
- **Why stopped:** Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02588261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02588261, "A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02588261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*